| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-08-06 | Oxygen Biotherapeutics (USA - NC) Imperial College London (UK) | levosimendan | prevention of acute organ dysfunction in sepsis | clinical research agreement |
Critical care - Infectious diseases | Clinical research agreement |
| 2014-08-06 | Yabao Pharmaceutical (China) Changzhou Le Sun Pharmaceuticals (China) | LS-008 | development agreement |
Cancer - Oncology | Development agreement | |
| 2014-08-06 | Orexo (Sweden) Boehringer Ingelheim (Germany) | OX-MPI project | undisclosed | licensing agreement |
undisclosed | Licensing agreement |
| 2014-08-05 | Ariad Pharmaceuticals (USA - MA) Medison Pharma (Israel) | Iclusig® (ponatinib) | Philadelphia -positive (Ph+) leukemias | Cancer - Oncology - Rare diseases | Commercialisation agreement | |
| 2014-08-05 | Regulus Therapeutics (USA - CA) BiogenIdec (USA - MA) | microRNAs as biomarkers for multiple sclerosis | multiple sclerosis | Autoimmune diseases - Neurodegenerative diseases | R&D agreement | |
| 2014-08-05 | Synthetic Biologics (USA - MD) Evonik (Germany) | formulation services for SYN-004 | prevention of Clostridium difficile infections | collaboration services |
Technology - Services - Infectious diseases | Services contract |
| 2014-08-04 | Impax Laboratories (USA - CA) | Rytary™ (extended-release capsule formulation of carbidopa and levodopa) | Parkinson\'s disease | Neurodegenerative diseases | Validation of a production plant | |
| 2014-08-04 | Infinity Pharmaceuticals (USA - MA) Millennium, the Takeda Oncology Company (USA - MA) | IPI-145 | hematological cancers | licensing agreement | Cancer - Oncology | Exercise of an option agreement |
| 2014-08-04 | Merck Serono (Germany) Kadimastem (Israel) | drug screening assays using stem cell-derived astrocytes | multiple sclerosis, other neurodegenerative diseases | collaboration agreement |
Neurodegenerative diseases | Collaboration agreement |
| 2014-08-04 | Medivir (Sweden) Boehringer Ingelheim (Germany) | Respiratory Syncytial Virus (RSV) drug program | Respiratory Syncytial Virus (RSV) infection | Infectious diseases | Licensing agreement | |
| 2014-08-04 | Ignyta (USA - CA) Nerviano Medical Sciences (Italy) | RXDX-103, RXDX-104 | multiple cancers | licensing agreement |
Cancer - Oncology | Licensing agreement |
| 2014-08-01 | Molecular Profiles (UK) a subsidiary of Columbia Laboratories (USA - MA), XenoGesis (UK) | development services | Technology - Services | Collaboration agreement | ||
| 2014-08-01 | Pfizer (USA - NY) Roche (Switzerland) ADDPLAN DF Consortium | Collaboration agreement | ||||
| 2014-08-01 | Abbvie (USA - IL) Cystic Fibrosis Research Inc (CFRI) (USA - CA) | CFChef Shares program | cystic fibrosis | collaboration agreement |
Rare diseases - Genetic diseases | Collaboration agreement |
| 2014-07-31 | Pluristem Therapeutics (Israel) | 3D cell therapy manufacturing processes | validation of a production plant |
Regenerative medicine | Validation of a production plant | |
| 2014-07-31 | Molecular Profiles (UK) , a subsidiary of Columbia Laboratories (USA - MA) XenoGesis (UK) | Technology - Services | Collaboration agreement | |||
| 2014-07-31 | Isis Innovation (UK) University of Oxford (UK) Rogne Bioscience (USA - CA) | anti-inflammatory peptides | psoriasis | Autoimmune diseases - Dermatological diseases | Licensing agreement | |
| 2014-07-30 | Dendreon (USA - WA) | president and chief executive officer | nomination | Cancer - Oncology | Nomination | |
| 2014-07-30 | AstraZeneca (UK) Kyowa Hakko Kirin (Japan) | MEDI4736, mogamulizumab, tremelimumab | clinical research |
Cancer - Oncology | Clinical research agreement | |
| 2014-07-29 | Genentech, a member of the Roche Group (USA - Switzerland) Incyte (USA - DE) | indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and PD-L1 immune checkpoint inhibitor, MPDL3280A (atezolizumab), | non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
